Nektar Therapeutics (NKTR) Other Accumulated Expenses (2010 - 2026)

Nektar Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 65.67% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 65.67% YoY), while the FY2025 annual figure was $2.7 million, down 72.59% from the prior year.
• Other Accumulated Expenses was $4.1 million for Q1 2026 at Nektar Therapeutics, up from $2.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $17.9 million in Q3 2024 to a low of $2.7 million in Q4 2025.
• Historically, Other Accumulated Expenses has averaged $10.4 million across 5 years, with a median of $11.1 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses jumped 185.8% in 2024, then tumbled 72.59% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $7.0 million in 2022, then tumbled by 50.44% to $3.5 million in 2023, then surged by 185.8% to $9.9 million in 2024, then sank by 72.59% to $2.7 million in 2025, then surged by 49.21% to $4.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $4.1 million (Q1 2026), $2.7 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.